文献速递糖尿病

速效门冬胰岛素与门冬胰岛素分别联合德谷胰岛素伴或不伴二甲双胍治疗成人2型糖尿病的随机试验(ONSET 9)

A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9).
PubMed 文献 · Diabetes Care · 2020-03-24

速效门冬胰岛素在HbA1c自基线变化上非劣于门冬胰岛素,在餐后血糖控制上优效,且严重或血糖确认低血糖发生率更低。

要点

  • 速效门冬胰岛素HbA1c自基线变化非劣于门冬胰岛素(ETD -0.04%)。
  • 速效门冬胰岛素餐后1小时血糖增量改善优于门冬胰岛素。
  • 速效门冬胰岛素严重或血糖确认低血糖发生率显著低于门冬胰岛素。

核心结论

  • 在联合德谷胰岛素治疗时,速效门冬胰岛素相比门冬胰岛素提供有效的总体血糖控制、更优的餐后血糖控制以及更低的严重或血糖确认低血糖发生率。

研究设计与样本

  • 多中心、双盲、达标治疗试验,随机分配速效门冬胰岛素组(n=546)或门冬胰岛素组(n=545)。
  • 研究对象为基础-餐时方案控制不佳的成人2型糖尿病患者。
  • 两组均联合德谷胰岛素伴或不伴二甲双胍。
  • 所有可用信息均用于疗效评估,无论是否终止治疗或使用辅助治疗。

主要发现

  • 随机化后16周HbA1c自基线变化(主要终点):速效门冬胰岛素 vs 门冬胰岛素 ETD -0.04%(95% CI -0.11; 0.03);-0.39 mmol/mol(-1.15; 0.37);P < 0.001,非劣效成立。
  • 餐试验1小时餐后血糖增量自基线变化:速效门冬胰岛素 vs 门冬胰岛素 ETD -0.40 mmol/L(-0.66; -0.14);-7.23 mg/dL(-11.92; -2.55);优效性 P = 0.001。
  • 自我监测所有餐次平均1小时餐后血糖增量自基线变化:速效门冬胰岛素 vs 门冬胰岛素 ETD -0.25 mmol/L(-0.42; -0.09);-4.58 mg/dL(-7.59; -1.57);P = 0.003。
  • 治疗期间严重或血糖确认低血糖总体发生率:速效门冬胰岛素 vs 门冬胰岛素估计治疗比 0.81(95% CI 0.68; 0.97),速效门冬胰岛素组显著更低。

关键数值与推荐

  • 主要终点为非劣效设计:HbA1c自基线变化16周,速效门冬胰岛素 vs 门冬胰岛素 ETD -0.04%(95% CI -0.11; 0.03),P < 0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of fast-acting insulin aspart (faster aspart) compared with insulin aspart (IAsp), both with insulin degludec with or without metformin, in adults with type 2 diabetes not optimally controlled with a basal-bolus regimen. RESEARCH DESIGN AND METHODS: This multicenter, double-blind, treat-to-target trial randomized participants to faster aspart (n = 546) or IAsp (n = 545). All available information, regardless of treatment discontinuation or use of ancillary treatment, was used for evaluation of effect. RESULTS: Noninferiority for the change from baseline in HbA1c 16 weeks after randomization (primary end point) was confirmed for faster aspart versus IAsp (estimated treatment difference [ETD] -0.04% [95% CI -0.11; 0.03]; -0.39 mmol/mol [-1.15; 0.37]; P < 0.001). Faster aspart was superior to IAsp for change from baseline in 1-h postprandial glucose (PPG) increment using a meal test (ETD -0.40 mmol/L [-0.66; -0.14]; -7.23 mg/dL [-11.92; -2.55]; P = 0.001 for superiority). Change from baseline in self-measured 1-h PPG increment for the mean over all meals favored faster aspart (ETD -0.25 mmol/L [-0.42; -0.09]); -4.58 mg/dL [-7.59; -1.57]; P = 0.003). The overall rate of treatment-emergent severe or blood glucose (BG)-confirmed hypoglycemia was statistically significantly lower for faster aspart versus IAsp (estimated treatment ratio 0.81 [95% CI 0.68; 0.97]). CONCLUSIONS: In combination with insulin degludec, faster aspart provided effective overall glycemic control, superior PPG control, and a lower rate of severe or BG-confirmed hypoglycemia versus IAsp in adults with type 2 diabetes not optimally controlled with a basal-bolus regimen.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Lane WS, Favaro E, Rathor N, et al. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9). Diabetes Care. 2020. PMID: 32209647. doi:10.2337/dc19-2232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。